Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448380 · ClinicalTrials.gov registry record
FreeStyle Libre Flash Glucose Monitoring System Post Approval Study
A clinical trial, sponsored by Abbott Diabetes Care.
- Completed
- Registry status
- 935
- Enrollment target
NCT03448380: Completed study, sponsored by Abbott Diabetes Care.
NCT03448380 is a clinical trial that has completed, run by Abbott Diabetes Care. The registered enrollment target is 935 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03448380 has completed, sponsored by Abbott Diabetes Care.
- COMPLETED
- Registry status
- 935 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, non-randomized, single-arm, post-approval study of the FreeStyle Libre Flash Glucose Monitoring System intended to characterize the safety of the Libre Flash Glucose Monitoring System when used in people with diabetes.
Primary Outcome
The study is designed to characterize the safety of the FreeStyle Libre Flash Glucose Monitoring System when used in the intended study population.
Interventions
- DEVICE FreeStyle Libre Flash Glucose Monitoring System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 935 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2021-03-30 |
What the finished NCT03448380 record still lists
NCT03448380 is an observational study that tracks outcomes without assigning an intervention. The registered 935 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which FreeStyle Libre Flash Glucose Monitoring System is the first listed.
NCT03448380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03448380 about?
NCT03448380 is a clinical study titled "FreeStyle Libre Flash Glucose Monitoring System Post Approval Study". This is a prospective, multi-center, non-randomized, single-arm, post-approval study of the FreeStyle Libre Flash Glucose Monitoring System intended to characterize the safety of the Libre Flash Glucose Monitoring System when used in people with diabetes.
What is the current status of trial NCT03448380?
This trial is currently completed. The enrollment target is 935 participants. The study started on 2018-02-27. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT03448380?
The interventions under investigation include: FreeStyle Libre Flash Glucose Monitoring System (DEVICE).
Who is sponsoring clinical trial NCT03448380?
This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI